HTA submission

What is an HTA submission?

An HTA submission is a formal package that presents the full clinical, economic and wider value proposition of a therapy to a national or regional body responsible for health technology assessment. It supports an assessment of whether the therapy should be reimbursed, funded or included on a formulary, and under what conditions.

The package typically combines clinical trial results, comparative evidence, real-world evidence, epidemiology, cost-effectiveness modelling and budget impact analysis. It also explains the relevant patient population, unmet need, place in the treatment pathway and expected effect on patients and health services. Required formats, methods and evidence vary by country and agency.

Why does an HTA submission matter in market access?

A positive HTA outcome is often a prerequisite for reimbursement and formulary inclusion. The submission therefore connects the product’s evidence and value claims with the questions that payers and assessment committees use to make funding decisions.

For market access teams, submission quality can affect the timing and conditions of access, the ability to justify price, and the need for restrictions, further evidence or commercial agreements. It also establishes a documented position that may need to be updated when new indications, comparators, prices or data become available.

How is an HTA submission prepared in practice?

Preparation starts by interpreting the agency’s scope, methods and submission template. The team defines the decision problem, including the population, intervention, comparators, outcomes, treatment setting and analytical perspective. It then aligns the clinical evidence, economic model and narrative around that question.

Typical work includes:

• selecting and synthesising relevant clinical and comparative evidence
• estimating disease burden, eligible population and current treatment patterns
• developing cost-effectiveness and budget impact models
• testing assumptions and uncertainty through sensitivity and scenario analyses
• documenting data sources, limitations and model validation
• adapting global evidence to local clinical practice, costs, comparators and policy requirements
• preparing responses for clarification questions, committee meetings or appraisal stages

Gaps identified during planning may need to be addressed through an evidence generation programme, rather than being managed only when the submission deadline approaches.

What does a good HTA submission look like?

A good submission is internally consistent, transparent and focused on the assessment question. Claims in the narrative should be traceable to the evidence, while model inputs should match the clinical data and the proposed patient population. Assumptions should be justified, uncertainty should be visible, and alternative scenarios should be easy for assessors to examine.

Common problems include using an inappropriate comparator, applying global assumptions without local validation, overstating immature evidence, or allowing the clinical narrative and economic model to describe different populations or outcomes. Technical accuracy alone is not enough if assessors cannot follow how the evidence supports the requested funding position.

Who owns an HTA submission?

Ownership is usually cross-functional. Market access commonly leads the strategy and agency engagement, while HEOR teams lead economic analyses and evidence synthesis. Medical affairs, clinical development, regulatory, epidemiology, biostatistics, finance and local affiliates may contribute evidence, interpretation and review. Legal or compliance teams may also review the final materials where required.

Clear governance is important because late changes to price, population, clinical claims or model assumptions can affect several parts of the package. Teams should define decision rights, review stages, source control and responsibility for responding to assessors before drafting begins.

How is an HTA submission different from related value documents?

An HTA submission is the agency-specific package used in a formal assessment. A global value dossier is usually an internal source document that brings together the evidence and value story for adaptation across markets. It does not replace the local submission template, economic methods or country-specific evidence requirements.

The submission is also distinct from the HTA itself. The company produces the submission; the assessment body reviews the evidence, may conduct or commission additional analysis, and reaches a recommendation or decision within its remit. Pricing negotiation, reimbursement implementation and formulary decisions may then follow as separate but connected processes.